Warfarin
Athrombin-k, Jantoven, Warfarin (warfarin) is a small molecule pharmaceutical. Warfarin was first approved as Athrombin-k on 1982-01-01. It is used to treat atrial fibrillation, postoperative complications, pulmonary embolism, stroke, and thromboembolism amongst others in the USA. The pharmaceutical is active against vitamin K epoxide reductase complex subunit 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Jantoven, Warfarin (discontinued: Athrombin-k, Coumadin, Panwarfin, Warfarin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Warfarin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PANWARFIN | Abbott Biotherapeutics | N-017020 DISCN | 1982-01-01 | 5 products |
| COUMADIN | Bristol Myers Squibb | N-009218 DISCN | 1982-01-01 | 12 products |
| ATHROMBIN | Pharmaceutical Research Associates Inc | N-011771 DISCN | 1982-01-01 | 3 products |
Hide discontinued
Warfarin potassium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ATHROMBIN-K | Pharmaceutical Research Associates Inc | N-011771 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acne cleanser | OTC monograph final | 2018-01-09 |
| americas choice hand sanitizer | OTC monograph not final | 2020-09-23 |
| audiologists choice earwax removal aid drops | C200263 | 2025-02-28 |
| audiologists choice earwax removal system | C200263 | 2023-12-15 |
| audiologists choice earwax removal system earwax removal | OTC monograph final | 2014-12-16 |
| awaken by quality choice absolute daily moisturizer broad spectrum spf 15 sunscreen | OTC monograph not final | 2014-09-18 |
| awaken by quality choice anti-wrinkle and firming moisturizer day broad spectrum spf18 sunscreen | OTC monograph not final | 2014-09-30 |
| awaken by quality choice foaming hand wash | OTC monograph not final | 2016-08-22 |
| awaken by quality choice illuminating daily moisturizer broad spectrum spf 15 sunscreen | OTC monograph not final | 2014-10-01 |
| awaken by quality choice long-lasting oil-free moisturizer broad spectrum spf 15 | OTC monograph not final | 2014-09-30 |
Show 243 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9143 | Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s) |
| Level 2: G9143-G9143 | Warfarin Responsiveness Testing |
Clinical
Clinical Trials
741 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | 2 | 1 | 2 | 11 | 15 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 4 | 3 | 7 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 4 | 2 | — | 6 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | 1 | 4 | 5 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | 2 | 1 | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 3 | — | 3 |
| Coronary occlusion | D054059 | — | I21 | — | — | — | 3 | — | 3 |
| Thrombosis | D013927 | — | — | — | — | — | 2 | — | 2 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 2 | — | 2 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | — | — | 2 | — | 2 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | 1 | 1 | — | — | 2 |
| Hepatitis c | D006526 | — | B19.2 | — | — | 2 | — | — | 2 |
| Hepatitis | D006505 | — | K75.9 | — | — | 2 | — | — | 2 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | 1 | — | — | 1 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | 1 | 1 | — | — | 1 |
| Systolic murmurs | D054160 | — | R01.1 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 3 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 3 | 3 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 2 | 2 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 2 | 2 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 2 | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | — | 2 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 2 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Thromboembolism | D013923 | — | — | — | — | — | — | 1 | 1 |
| Glycemic control | D000085002 | — | — | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Warfarin |
| INN | warfarin |
| Description | 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one is a member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group. It is a methyl ketone and a hydroxycoumarin. |
| Classification | Small molecule |
| Drug class | warfarin analogs |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O |
Identifiers
| PDB | — |
| CAS-ID | 129-06-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1464 |
| ChEBI ID | 87732 |
| PubChem CID | 54678486 |
| DrugBank | DB00682 |
| UNII ID | 5Q7ZVV76EI (ChemIDplus, GSRS) |
Target
Agency Approved
VKORC1
VKORC1
Organism
Homo sapiens
Gene name
VKORC1
Gene synonyms
VKOR
NCBI Gene ID
Protein name
vitamin K epoxide reductase complex subunit 1
Protein synonyms
phylloquinone epoxide reductase, vitamin K dependent clotting factors deficiency 2, Vitamin K1 2,3-epoxide reductase subunit 1, vitamin K1 epoxide reductase (warfarin-sensitive)
Uniprot ID
Mouse ortholog
Vkorc1 (27973)
vitamin K epoxide reductase complex subunit 1 (Q9CRC0)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Warfarin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 73,910 documents
View more details
Safety
Black-box Warning
Black-box warning for: Coumadin, Jantoven, Moms choice rx, Warfarin sodium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
59,965 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use